Suppression of follicular phase pituitary-gonadal function by a potent new gonadotropin-releasing hormone antagonist with reduced histamine-releasing properties (ganirelix) **Supported in part by Syntex Developmental Research, Palo Alto, California.-Reference-Cited by-同舟云学术

Suppression of follicular phase pituitary-gonadal function by a potent new gonadotropin-releasing hormone antagonist with reduced histamine-releasing properties (ganirelix) **Supported in part by Syntex Developmental Research, Palo Alto, California.

Published:1995-05 Issue:5 Volume:63 Page:963-969
ISSN:0015-0282
Container-title:Fertility and Sterility
language:en
Short-container-title:Fertility and Sterility

Author:

Nelson Linda R.,Fujimoto Victor Y.,Jaffe Robert B.,Monroe Scott E.

Publisher

Elsevier BV

Subject

Obstetrics and Gynecology,Reproductive Medicine

Reference25 articles.

1. The biochemistry, physiology, and pharmacology of gonadotropin releasing hormone (GnRH) and GnRH analogues;Friedman,1991

2. The molecular basis of gonadotropin-releasing hormone action;Conn;Endocrinol Rev,1986

3. Concordant suppression of serum immunoreactive luteinizing hormone (LH), follicle-stimulating hormone, α-subunit, bioactive LH, and testosterone in postmenopausal women by a potent gonadotropin releasing hormone antagonist (detirelix);Andreyko;J Clin Endocrinol Metab,1992

4. Differential regulation of luteinizing hormone, follicle-stimulating hormone, and free α-subunit secretion from the gonadotrope by gonadotropin-releasing hormone (GnRH): evidence from the use of two GnRH antagonists;Hall;J Clin Endocrinol Metab,1990

5. Treatment of endometriosis with a potent agonist of gonadotropin-releasing hormone (nafarelin);Schriock;Fertil Steril,1985

Cited by 46 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Efficacy and safety of newly developed ganirelix acetate in infertile women for assisted reproductive technology: a prospective, randomised, controlled study;Journal of Obstetrics and Gynaecology;2022-03-07

2. Dynamic Interactions Between LH and Testosterone in Healthy Community-Dwelling Men: Impact of Age and Body Composition;The Journal of Clinical Endocrinology & Metabolism;2019-12-02

3. Elagolix Suppresses Ovulation in a Dose-Dependent Manner: Results From a 3-Month, Randomized Study in Ovulatory Women;The Journal of Clinical Endocrinology & Metabolism;2019-10-25

4. Relugolix. GnRH (LHRH) receptor antagonist, Treatment of uterine fibroids, Treatment of endometriosis-related pain, Treatment of prostate cancer;Drugs of the Future;2019

5. Targeting luteinizing hormone-releasing hormone: A potential therapeutics to treat gynecological and other cancers;Journal of Controlled Release;2018-01